HealthGovernment Caps Trade Margin at 30% for Non-Scheduled Cancer Drugs
The government has limited the trade margin on non-scheduled anti-cancer drugs to 30%, aiming to reduce the cost burden on patients. This move could lead to a reduction in the maximum retail price (MRP) of these drugs by up to 70%. The decision targets making cancer treatment more affordable by regulating drug pricing.
Amar Ujala·


